Adalimumab has the potential to serve an important role in management of chronic and refractory noninfectious uveitis and associated macular edema with low rates of serious adverse events in the long term, according to a recent report. That includes pediatric patients.
Adalimumab (ADA) works well as a treatment for patients with both active and inactive uveitis whether or not they are taking an immunosuppressant (IMM); however, the median time to treatment failure (mTTF) is longer for patients with inactive uveitis taking an IMM.
As with most surgical advances, new potential procedures in ophthalmology pose their fair share of risks. However, if those risks can be overcome the rewards to patients can make a significant difference in their quality of life.
As a retinal implant, the ARGUS II technology has shown early benefits for patients with retinitis pigmentosa. A new study from the United Kingdom is examining its benefits in patients with the dry form of age related macular degeneration.
As with all new technologies for surgical procedures, there will be questions to be answered about the safety for hypersonic vitrectomy. While human trials have not started yet, there are good indications in cadaveric and animal studies.